On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
WednesdaySep 30, 2020 3:04 pm

Kaival Brands Innovations Group Inc. (KAVL) Releases Q3 Numbers, Revenues up by 44%

Q3 2020 revenue numbers paint a bright future for KAVL with revenue up by approximately 44% Company closely focused on expanding distribution into large national retailers, convenience chains during Q4 Much of Q3 activity centered around Bidi(TM) Sticks Kaival Brands Innovations Group (OTCQB: KAVL), a company focused on growing and incubating innovative and profitable products into mature, dominant brands, recently released its Q3 financial report. The report showed revenues for KAVL up by approximately 44% compared to Q2 2020. In addition, the report noted that national distribution channels are being established for future growth. “We had an extremely busy and…

Continue Reading

WednesdaySep 30, 2020 2:30 pm

Pure Extract Poised to Benefit as Mainstream Society Embraces Functional Mushrooms

Following $1.25 million donation, UC Berkeley launching Center for the Science of Psychedelics Pure Extract Technologies Inc. expanding into functional and medicinal mushroom market Psychedelic compounds increasingly being studied to treat wide range of physical, mental conditions Pure Extracts plans to obtain a Natural Health Products Site License from Health Canada to buy, sell, functional mushroom products For hundreds of years, medicinal mushrooms have been revered among both ancient and modern cultures throughout the world for their nutritional and medicinal qualities. Pure Extract Technologies, a private plant-based Canadian extraction company headquartered in British Columbia, is leveraging the latest in science…

Continue Reading

WednesdaySep 30, 2020 1:53 pm

QualityStocksNewsBreaks – Blue Hat Interactive Entertainment Technology (NASDAQ: BHAT) Enters Updated LOI to Acquire 51% of Mobile Game Developer Csfctech

Blue Hat Interactive Entertainment Technology (NASDAQ: BHAT), a leading producer, developer and operator of augmented reality ("AR") interactive entertainment games, toys and educational materials in China, today announced its entry into an updated letter of intent (“LOI”). Under the terms of the LOI, BHAT will acquire the control of 51% of Fuzhou Csfctech Co. Ltd. ("Csfctech") and its two subsidiaries through the direct acquisition of 51% of the outstanding shares of its offshore holding company. Csfctech is a developer and distributor of mobile games with an international user base across Mainland China, Japan, Taiwan, the United Arab Emirates and Africa.…

Continue Reading

WednesdaySep 30, 2020 10:24 am

QualityStocksNewsBreaks – Sugarmade Inc. (SGMD) Signs Agreement for Property to Use for Planned Cannabis Cultivation

Sugarmade (SGMD) a leading, multidivisional/multiproduct/multisector supply company, has entered into a property lease agreement with LMK Capital LLC. The agreement includes five acres of cropland located in Northern California, which has been zoned for cannabis cultivation. Sugarmade plans to use the property to operate a licensed cannabis production business, which it anticipates may produce up to 3.6 million grams of high-quality cannabis flower annually. The company’s strategic plan calls for marketing the cannabis as both white-label and branded cannabis products through various distributors. Among those distributors will be BudCars Cannabis Delivery Service (“BudCars”), a cannabis delivery company that is seeing…

Continue Reading

WednesdaySep 30, 2020 10:15 am

QualityStocksNewsBreaks – Creatd Inc. (NASDAQ: CRTD) Appoints New COO to Lead Growth Strategy, Manage Partnership Initiatives

Creatd (NASDAQ: CRTD, CRTDW), the parent company and creator of the Vocal platform, today announced the appointment of Laurie Weisberg as its new chief operating officer. Weisberg currently sits on Creatd’s board of directors and will lead the company's sales team in the execution of its growth strategy and manage all strategic partnership initiatives. This appointment aligns with Creatd's 2021 plans to broaden and scale its product line and revenues, including Vocal for Brands, Seller's Choice, and Vocal+ paid subscriptions. "I have closely observed the Creatd team over the last year, particularly since I assumed my role as a member…

Continue Reading

WednesdaySep 30, 2020 9:55 am

QualityStocksNewsBreaks – Siyata Mobile Inc. (TSX.V: SIM) (OTCQX: SYATF) Closes Upsized NASDAQ Initial Public Offering

Siyata Mobile (TSX.V: SIM) (OTCQX: SYATF) (NASDAQ: SYTA, SYTAW), a leading global developer and provider of Push-to-Talk Over Cellular (“PTT/PoC”) systems for enterprise customers, has announced the closing of its upsized $12.6 million U.S. initial public offering on the NASDAQ. The company had previously announced the IPO of 2,100,000 units at a price of $6 per unit, with each unit comprised of one common share in the capital of the company and one warrant to purchase one common share in the capital of the company. The shares and warrants were issued separately and were approved to list on the Nasdaq…

Continue Reading

WednesdaySep 30, 2020 9:35 am

QualityStocksNewsBreaks – VistaGen Therapeutics (NASDAQ: VTGN) CEO Addresses ‘Multi-Pronged Approach’ to Growing Problem of Workplace Stress and Anxiety

VistaGen Therapeutics’ (NASDAQ: VTGN) CEO Shawn Singh authored a recent article for Business.com regarding the COVID-19 pandemic and resulting stress and anxiety impacts to the workplace. In the piece, Singh indicates that stress and anxiety, often driven by job-related issues, when left unchecked can rise to the level of an anxiety disorder with negative consequences for physical health, mental well-being, productivity and career opportunities. The global pandemic has exacerbated this largely unaddressed and widespread mental health problem in the workplace, markedly reflecting in increased prescriptions for antidepressant and anti-anxiety medications, many associated with significant side effects and safety concerns. “To…

Continue Reading

TuesdaySep 29, 2020 2:52 pm

QualityStocksNewsBreaks – VistaGen Therapeutics (NASDAQ: VTGN) CEO Discusses PH94B Drug Candidate in Applied Clinical Trials Publication

VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, was recently featured in an Applied Clinical Trials article titled, “Pushing Late-Stage Treatments Forward in the Clinic.” In the article, VistaGen’s CEO Shawn Singh discussed the company's ongoing efforts to treat and help manage the anxiety symptoms provoked by COVID-19 and other triggers, anxiety-related disorders initially in subjects suffering from Social Anxiety Disorder (“SAD”), as well as the FDA’s consensus on the design of the company’s pivotal Phase III study of PH94B. The piece quotes Singh, who states, “Now…

Continue Reading

TuesdaySep 29, 2020 1:28 pm

Predictive Oncology Inc. (NASDAQ: POAI) Set to Capitalize on Increased AI Usage within Oncological Treatments

Predictive Oncology develops AI-solutions designed to assist clinicians in formulating personalized treatment plans for oncological patients Artificial Intelligence is being increasingly used to help understand and accurately predict how drug therapies can interact with specific patients POAI’s TumorGenesis subsidiary is also creating laboratory-grown tumors to help clinicians and researchers to better test therapies Predictive Oncology (NASDAQ: POAI), a knowledge-driven precision medicine company that focuses on applying data and artificial intelligence (“AI”) to cancer personalized medicine and drug discovery, is set to play a key role as the integration of AI technology within cancer care continues to improve the accuracy and…

Continue Reading

TuesdaySep 29, 2020 1:08 pm

QualityStocksNewsBreaks – MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) Pushes Bio-Pesticide Boundaries into New Continent with Currently Untreatable Pathogen

MustGrow (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) today announced the commencement of testing of its proprietary TerraMG bio-pesticide formulation on the Panama Disease (Fusarium wilt TR4), a devastating disease pathogen ravaging the $25 billion global banana industry. MustGrow's TerraMG bio-pesticide has been proven to control similar soil-borne diseases, and the testing work will build on MustGrow's existing field data and serve as a benchmark for achieving registration labels in Colombia and other leading South American agricultural countries. "This is an exciting program for MustGrow, as we push the boundaries of our bio-pesticide into a new continent with a currently untreatable…

Continue Reading

Market Basics

New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

The Basics

Newsletter Publishers

Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.


Public Companies

Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

Get Covered